FORM OF PRE-FUNDED WARRANT SONNET BIOTHERAPEUTICS HOLDINGS, INC. PRE-FUNDED WARRANT TO PURCHASE COMMON STOCKSecurity Agreement • December 10th, 2024 • Sonnet BioTherapeutics Holdings, Inc. • Pharmaceutical preparations • New York
Contract Type FiledDecember 10th, 2024 Company Industry JurisdictionSonnet BioTherapeutics Holdings, Inc., a company organized under the laws of Delaware (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ], the registered holder hereof or its permitted assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, at any time or times on or after [ ], 2024 (the “Initial Exercisability Date”), until exercised in full (the “Termination Date”), [ ] fully paid non-assessable shares of Common Stock (as defined below), subject to adjustment as provided herein (the “Warrant Shares”). Except as otherwise defined herein, capitalized terms in this Warrant to Purchase Common Stock (including any Pre-Funded Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, this “Warrant”), shall have the meanings set forth in Section 16. This Warrant is issue
ContractSecurity Agreement • March 26th, 2021 • Alto Ingredients, Inc. • Industrial organic chemicals • New York
Contract Type FiledMarch 26th, 2021 Company Industry JurisdictionNEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.
ContractSecurity Agreement • October 26th, 2020 • Pacific Ethanol, Inc. • Industrial organic chemicals • New York
Contract Type FiledOctober 26th, 2020 Company Industry JurisdictionNEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.
DOLPHIN ENTERTAINMENT, INC. WARRANT TO PURCHASE COMMON STOCKSecurity Agreement • March 30th, 2020 • Dolphin Entertainment, Inc. • Services-personal services • New York
Contract Type FiledMarch 30th, 2020 Company Industry JurisdictionDolphin Entertainment, Inc., a Florida corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, M. Shanken Communications, Inc., the registered holder hereof or its permitted assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, upon exercise of this Series I Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, this “Warrant”), at any time or times on or after the Initial Exercise Date, but not after 11:59 p.m., New York time, on the Expiration Date (as defined below), 100,000 (subject to adjustment as provided herein) fully paid and non-assessable shares of Common Stock (as defined below) (the “Warrant Shares”). Except as otherwise defined herein, capitalized terms in this Warrant shall have the meanings se
AZURRX BIOPHARMA, INC. Warrant To Purchase Common StockSecurity Agreement • July 22nd, 2019 • AzurRx BioPharma, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJuly 22nd, 2019 Company Industry JurisdictionAzurRx BioPharma, Inc., a company organized under the laws of Delaware (the "Company"), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ___________, the registered holder hereof or its permitted assigns (the "Holder"), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, at any time or times on or after July __, 2019 (the “Initial Exercisability Date”), but not after 11:59 p.m., New York time, on July __, 2024 (the “Expiration Date”), _____ fully paid non-assessable shares of Common Stock (as defined below), subject to adjustment as provided herein (the "Warrant Shares"). Except as otherwise defined herein, capitalized terms in this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, this "Warrant"), shall have the meanings set forth in Section 16.
Westwater Resources, Inc. Warrant To Purchase Common StockSecurity Agreement • May 31st, 2019 • Westwater Resources, Inc. • Metal mining • Illinois
Contract Type FiledMay 31st, 2019 Company Industry JurisdictionWestwater Resources, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Lincoln Park Capital Fund, LLC, the registered holder hereof or its permitted assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, upon exercise of this Warrant to Purchase Common Stock (including any Warrant(s) to Purchase Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”), at any time or times on or after the Initial Exercise Date, but not after 11:59 p.m., New York time, on the Expiration Date (as defined below), 182,515 (subject to adjustment as provided herein) fully paid and non-assessable shares of Common Stock (as defined below) (the “Warrant Shares”). Except as otherwise defined herein, capitalized terms in this Warrant shall have the meanings set forth in
SELLAS LIFE SCIENCES GROUP, INC WARRANT TO PURCHASE COMMON STOCKSecurity Agreement • March 6th, 2019 • SELLAS Life Sciences Group, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMarch 6th, 2019 Company Industry JurisdictionSELLAS Life Sciences Group, Inc., a corporation organized under the laws of Delaware (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [HOLDER], the registered holder hereof or its permitted assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, at any time or times on or after the six-month anniversary of the Issuance Date (the “Initial Exercisability Date”), but not after 11:59 p.m., New York time, on the Expiration Date, (as defined below), ( ) fully paid non-assessable shares of Common Stock (as defined below), subject to adjustment as provided herein (the “Warrant Shares”). Except as otherwise defined herein, capitalized terms in this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, this “Warrant”), shall
CORMEDIX INC. SECOND Amended and Restated Warrant To Purchase Common StockSecurity Agreement • January 3rd, 2019 • CorMedix Inc. • Pharmaceutical preparations • New York
Contract Type FiledJanuary 3rd, 2019 Company Industry JurisdictionThis Second Amended and Restated Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”) of CorMedix Inc. (the “Company”) is issued this 31st day of December, 2018, and amends and restates the Warrant to Purchase Common Stock issued by the Company on October 22, 2013 (the “Issuance Date”) _________________ (the “Holder”) pursuant to that certain Securities Purchase Agreement dated October 17, 2013 (the “Securities Purchase Agreement”), which Warrant to Purchase Common Stock was subsequently amended and restated on September 15, 2014. The Company hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Holder or its permitted assigns is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, upon exercise of this Warrant, at any time or times on or a
CORMEDIX INC. THIRD AMENDED AND RESTATED WARRANT TO PURCHASE COMMON STOCKSecurity Agreement • January 3rd, 2019 • CorMedix Inc. • Pharmaceutical preparations • New York
Contract Type FiledJanuary 3rd, 2019 Company Industry JurisdictionThis Third Amended and Restated Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”) of CorMedix Inc. (the “Company”) is issued this 31st day of December 2018, and amends and restates the Warrant to Purchase Common Stock issued by the Company on May 30, 2013 (the “Issuance Date”) to Manchester Securities Corp. (the “Holder”), pursuant to that certain Securities Purchase Agreement dated May 23, 2013 (the “Securities Purchase Agreement”), which Warrant to Purchase Common Stock was subsequently amended and restated on September 15, 2014 and March 3, 2015. The Company hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Holder or its permitted assigns is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, upon exercise of this Warrant, at any
BIOPHARMX CORPORATION WARRANT TO PURCHASE COMMON STOCKSecurity Agreement • December 7th, 2018 • BioPharmX Corp • Pharmaceutical preparations • New York
Contract Type FiledDecember 7th, 2018 Company Industry JurisdictionBioPharmX Corporation, a company organized under the laws of Delaware (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, , the registered holder hereof or its permitted assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, at any time or times during the Exercise Period, but not after 11:59 p.m., New York time, on the Expiration Date, (as defined below), ( ) fully paid non-assessable shares of Common Stock (as defined below), subject to adjustment as provided herein (the “Warrant Shares”). Except as otherwise defined herein, capitalized terms in this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, this “Warrant”), shall have the meanings set forth in Section 16. This Warrant is one of the Warrants to Purchase
AZURRX BIOPHARMA, INC. Warrant To Purchase Common StockSecurity Agreement • May 4th, 2018 • AzurRx BioPharma, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMay 4th, 2018 Company Industry JurisdictionAzurRx BioPharma, Inc., a company organized under the laws of Delaware (the "Company"), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ______________, the registered holder hereof or its permitted assigns (the "Holder"), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, at any time or times on or after ______________ (the “Initial Exercisability Date”), but not after 11:59 p.m., New York time, on ______________ (the “Expiration Date”), ______________ fully paid non-assessable shares of Common Stock (as defined below), subject to adjustment as provided herein (the "Warrant Shares"). Except as otherwise defined herein, capitalized terms in this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, this "Warrant"), shall have the meanings set forth i
CORMEDIX INC. Amended and Restated Warrant To Purchase Common StockSecurity Agreement • March 4th, 2015 • CorMedix Inc. • Pharmaceutical preparations • New York
Contract Type FiledMarch 4th, 2015 Company Industry JurisdictionThis Amended and Restated Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”) of CorMedix Inc. (the “Company”) is issued this 3rd day of March 2015, and amends and restates the Warrant to Purchase Common Stock issued by the Company on May 30, 2013 (the “Issuance Date”) to Manchester Securities Corp. (the “Holder”), pursuant to that certain Securities Purchase Agreement dated May 23, 2013 (the “Securities Purchase Agreement”), which Warrant to Purchase Common Stock was subsequently amended and restated on September 15, 2014. The Company hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Holder or its permitted assigns is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, upon exercise of this Warrant, at any time or times on or after M
Amended and Restated Warrant To Purchase Common StockSecurity Agreement • September 16th, 2014 • CorMedix Inc. • Pharmaceutical preparations • New York
Contract Type FiledSeptember 16th, 2014 Company Industry JurisdictionThis Amended and Restated Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”) of CorMedix Inc. (the “Company”) is issued this 15 day of September, 2014, and amends and restates the Warrant to Purchase Common Stock issued by the Company on January 8, 2014 (the “Issuance Date”) to ______________________ (the “Holder”) pursuant to that certain Securities Purchase Agreement dated January 7, 2014 (the “Securities Purchase Agreement”). The Company hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Holder or its permitted assigns is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, upon exercise of this Warrant, at any time or times on or after January 8, 2014 (the “Initial Exercisability Date”), but not after 11:59 p.m., New York time, on
Amended and Restated Warrant To Purchase Common StockSecurity Agreement • September 16th, 2014 • CorMedix Inc. • Pharmaceutical preparations • New York
Contract Type FiledSeptember 16th, 2014 Company Industry JurisdictionThis Amended and Restated Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”) of CorMedix Inc. (the “Company”) is issued this 15 day of September, 2014, and amends and restates the Warrant to Purchase Common Stock issued by the Company on October 22, 2013 (the “Issuance Date”) to ______________________ (the “Holder”) pursuant to that certain Securities Purchase Agreement dated October 17, 2013 (the “Securities Purchase Agreement”). The Company hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Holder or its permitted assigns is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, upon exercise of this Warrant, at any time or times on or after October 22, 2014 (the “Initial Exercisability Date”), but not after 11:59 p.m., New York time,